Beata Beatrix : La Vita Nuova e i quadri di Dante Gabriel Rossetti

Il contributo intende proporre un primo percorso attraverso la rilettura della Vita Nuova in ambito preraffaellita, esaminando la raffinata edizione della Vita Nuova illustrata dai quadri di Dante Gabriel Rossetti pubblicata per Roux e Viarengo all'inizio del '900. L'edizione, postuma, non nasce da un preciso progetto illustrativo autoriale, pur accarezzato dal poeta-pittore fin da giovanissimo, ma mette insieme a posteriori le riproduzioni di alcune opere rossettiane a illustrazione del libello dantesco, non senza arbitrarietà. Emerge tuttavia un costante impegno dell'artista su questi soggetti che, accanto al lavoro di traduzione sulla stessa Vita Nuova e sui "poeti primitivi italiani", e insieme con la sua produzione poetica e letteraria (almeno The Blessed Damozel e Hand and Soul), dimostra una profonda riappropriazione del testo, caratterizzata al contempo da una certa fedeltà letterale non in contraddizione con una rivisitazione profonda in tutt'altro contesto storico-artistico.The aim of the paper is to propose a first path through the rereading of the Vita Nuova within the Pre-Raphaelite culture, examining the refined edition of the Vita Nuova illustrata dai quadri di Dante Gabriel Rossetti, published by Roux and Viarengo in early '900. This posthumous edition is not the result of a specific illustrative authorial project, although the poet-painter had aimed for this since his early age; it is rather an a posteriori and partly arbitrary collection, which puts together the reproductions of some Rossetti's illustrations from Dante's pamphlet. The artist never stopped working on these subjects, translating at the same time Dante's Vita Nuova and other Early Italian Poets, while working on his own poetic and literary production (The Blessed Damozel and Hand and Soul, at least): this demonstrates a deep repossession of the text, which is characterized by a certain literal accuracy, but also by a deep revision, according to a completely different historical and artistic context

Concientización a la población estudiantil de la Universidad Nacional de Córdoba sobre la enfermedad celíaca

La igualdad nutricional es un derecho difícil de lograr para las personas que deben adherir a una dieta libre de gluten, particularmente en Argentina por la cultura social-nutricional, donde pizzas, empanadas, pastas y cervezas, están fuertemente asociadas a percepciones individuales de lo placentero y festejo compartido. El proyecto de extensión “Aglutinar sin Gluten” tiene dentro de sus objetivos específicos: “Informar y concientizar de la problemática a la comunidad de la Universidad Nacional de Córdoba”, para tratar de aportar a la igualdad alimentaria de los estudiantes y de la comunidad en general. Se elaboraron un total de 1000 encuestas y se entregaron a partir del mes de marzo junto al comienzo de la actividad educativa, 450 al comedor Universitario y 650 a la Dirección de Salud de la SAE, una mayor cantidad a esta última debido a que los estudiantes tenían la obligación de entregarla junto con la información solicitada en su chequeo médico. Se devolvieron 67 y 619 respectivamente, haciendo un total de 686 encuestados en los que solo dos fueron celíacos. En ambos lugares, se colocó un póster de la temática con respuestas de la encuesta, permitiendo de esta forma una lectura a conciencia de la información. La encuesta consistió en 14 preguntas y múltiple opciones generales sobre celiaquía, las preguntas permitieron respaldar la claridad de la elección de algunas múltiple opciones. La pregunta sobre que es Celiaquía, la respondieron 508 personas, donde el 56% respondió correctamente como la intolerancia a los cereales: Trigo, avena, cebada y centeno y no a una intolerancia a todas las harinas en general entre otra respuesta. Un 20% de los encuestados conoce personas celíacas y el 42 % mostró tener una relación directa o de primer grado con ésta. En relación a cual es el símbolo correcto, 86% de las 637 personas contestaron correctamente. En tanto a cual alimento no podría ofrecerle a una persona celíaca el 80% contestó correctamente mientras que sólo el 38% fue capaz de distinguir entre alimentos permitidos y no permitidos. Concluimos que aproximadamente la mitad de las personas encuestadas sabe que es la enfermedad celiaca y reconocen correctamente el logo, aunque un porcentaje muy alto no distingue un alimento libre de gluten. Aunque no se evaluó el conocimiento adquirido por los estudiantes, esta herramienta permitió concienciar a todos aquellos que respondieron la encuesta.

Role of 1p/19q Codeletion in Diffuse Low-grade Glioma Tumour Prognosis

Background/Aim: In the latest 2021 WHO classification of central nervous system tumours (CNS), gliomas that present isocitrate dehydrogenase (IDH) mutations are defined as diffuse low-grade gliomas (DLGGs). IDH mutations are commonly observed in this tumour type. The Extent of Resection (EOR) positively influence survival; however, it is still debated whether the predictive value of EOR is independent of the 1p/19q co-deletion. We carried out a retrospective analysis on patients operated on for DLGG at the Sant’Andrea University Hospital Sapienza University of Rome, correlating the outcome with the presence of 1p/19q co-deletion and EOR. Patients and Methods: The study examined 66 patients with DLGG who had undergone surgery for tumour resection between 2008 and 2018. Patients with DLGG were divided into two groups; diffuse astrocytoma (DA) in which 1p/19q codeletion is absent and oligodendroglioma (OG) in which 1p/19q codeletion is present. According to EOR, both groups were divided into two subgroups: subtotal resection (STR) and gross total resection (GTR). Three end-point variables were considered: overall survival (OS), progression-free survival (PFS) and time to malignant transformation (TMT). Results: In the DA group, the GTR subgroup had an average OS of 81.6 months, an average PFS of 45.9 months and an average TMT of 63.6 months. After surgery, these patients had an average Karnofsky Performance Score (KPS) of 83.4. The STR subgroup had an average OS of 60.4 months, PFS was 38.7 months, and TMT was 46.4 months, post-operative KPS was 83.4. In contrast, in the OG group, the GTR averagely had 101.7 months of OS, 64.9 months of PFS, 80.3 months of TMT and an average post-operative KPS of 84.2, and the STR subgroup had an average of OS of 73.3 months, PFS of 48.2 months, TMT of 57.3 and an average postoperative KPS of 96.2. Conclusion: In patients affected by DLGGs, 1p/19q codeletion is significantly associated with prolonged survival and longer time-to-malignant transformation (TMT) compared to the absence of 1p/19q codeletion. Also, the extent of surgical resection (EOR) in DLGG patients has been confirmed as one of the main prognostic factors. However, its predictive value is substantially influenced by the presence of the 1p/19q codeletion

The fading guardian: clinical relevance of TP53 null mutation in high-grade serous ovarian cancers

Backgroundwe evaluated the concordance between immunohistochemical p53 staining and TP53 mutations in a series of HGSOC. Moreover, we searched for prognostic differences between p53 overexpression and null expression groups.Methodspatients affected by HGSOC were included. For each case p53 immunohistochemical staining and molecular assay (Sanger sequencing) were performed. Kaplan-Meier survival analyses were undertaken to determine whether the type of TP53 mutation, or p53 staining pattern influenced overall survival (OS) and progression free survival (PFS).Results34 HGSOC were considered. All cases with a null immunohistochemical p53 expression (n=16) showed TP53 mutations (n=9 nonsense, n=4 in-frame deletion, n=2 splice, n=1 in-frame insertion). 16 out of 18 cases with p53 overexpression showed TP53 missense mutation. Follow up data were available for 33 out of 34 cases (median follow up time 15 month). We observed a significant reduction of OS in p53 null group [HR = 3.64, 95% CI 1.01-13.16].Conclusionimmunohistochemical assay is a reliable surrogate for TP53 mutations in most cases. Despite the small cohort and the limited median follow up, we can infer that HGSOC harboring p53 null mutations are a more aggressive subgroup

A View from the Past Into our Collective Future: The Oncofertility Consortium Vision Statement

Today, male and female adult and pediatric cancer patients, individuals transitioning between gender identities, and other individuals facing health extending but fertility limiting treatments can look forward to a fertile future. This is, in part, due to the work of members associated with the Oncofertility Consortium. The Oncofertility Consortium is an international, interdisciplinary initiative originally designed to explore the urgent unmet need associated with the reproductive future of cancer survivors. As the strategies for fertility management were invented, developed or applied, the individuals for who the program offered hope, similarly expanded. As a community of practice, Consortium participants share information in an open and rapid manner to addresses the complex health care and quality-of-life issues of cancer, transgender and other patients. To ensure that the organization remains contemporary to the needs of the community, the field designed a fully inclusive mechanism for strategic planning and here present the findings of this process. This interprofessional network of medical specialists, scientists, and scholars in the law, medical ethics, religious studies and other disciplines associated with human interventions, explore the relationships between health, disease, survivorship, treatment, gender and reproductive longevity. The goals are to continually integrate the best science in the service of the needs of patients and build a community of care that is ready for the challenges of the field in the future

Colorectal Cancer Stage at Diagnosis Before vs During the COVID-19 Pandemic in Italy

IMPORTANCE Delays in screening programs and the reluctance of patients to seek medical attention because of the outbreak of SARS-CoV-2 could be associated with the risk of more advanced colorectal cancers at diagnosis. OBJECTIVE To evaluate whether the SARS-CoV-2 pandemic was associated with more advanced oncologic stage and change in clinical presentation for patients with colorectal cancer. DESIGN, SETTING, AND PARTICIPANTS This retrospective, multicenter cohort study included all 17 938 adult patients who underwent surgery for colorectal cancer from March 1, 2020, to December 31, 2021 (pandemic period), and from January 1, 2018, to February 29, 2020 (prepandemic period), in 81 participating centers in Italy, including tertiary centers and community hospitals. Follow-up was 30 days from surgery. EXPOSURES Any type of surgical procedure for colorectal cancer, including explorative surgery, palliative procedures, and atypical or segmental resections. MAIN OUTCOMES AND MEASURES The primary outcome was advanced stage of colorectal cancer at diagnosis. Secondary outcomes were distant metastasis, T4 stage, aggressive biology (defined as cancer with at least 1 of the following characteristics: signet ring cells, mucinous tumor, budding, lymphovascular invasion, perineural invasion, and lymphangitis), stenotic lesion, emergency surgery, and palliative surgery. The independent association between the pandemic period and the outcomes was assessed using multivariate random-effects logistic regression, with hospital as the cluster variable. RESULTS A total of 17 938 patients (10 007 men [55.8%]; mean [SD] age, 70.6 [12.2] years) underwent surgery for colorectal cancer: 7796 (43.5%) during the pandemic period and 10 142 (56.5%) during the prepandemic period. Logistic regression indicated that the pandemic period was significantly associated with an increased rate of advanced-stage colorectal cancer (odds ratio [OR], 1.07; 95%CI, 1.01-1.13; P = .03), aggressive biology (OR, 1.32; 95%CI, 1.15-1.53; P < .001), and stenotic lesions (OR, 1.15; 95%CI, 1.01-1.31; P = .03). CONCLUSIONS AND RELEVANCE This cohort study suggests a significant association between the SARS-CoV-2 pandemic and the risk of a more advanced oncologic stage at diagnosis among patients undergoing surgery for colorectal cancer and might indicate a potential reduction of survival for these patients